Adults with newly diagnosed, aggressive non-Hodgkin lymphoma who receive intensive chemotherapy plus haemopoietic stem-cell transplantation have a better 5 year event-free survival than do patients who receive CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; N Engl J Med 2004; 350: 1287–95). “Our findings are important because they show that CHOP can no longer be regarded as the standard treatment for such patients”, explains Noel Milpied (University Hospital of Nantes, France).